Analyst Coverage
SPARK PLUS | From concept to clinic: Reframing the ALA opportunity. U.S. FDA IND acceptance and a well-funded clinical runway meaningfully improves Arovella’s investment profile.
MST ACCESS | CAR-iNKT, next gen cancer killer. Cutting-edge. Human trials start CY25. Undervalued.
A$0.34 valuation
SPARK PLUS | Describes Arovella’s current product pipeline and its ambitions to tackle a range of blood cancers and solid tumours.